Patrick Lin - 01 Jan 2024 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: Chief Business - Strategy Off
Signature: /s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol: PCSA
Transactions as of: 01 Jan 2024
Net transactions value: -$1,504
Form type: 4
Filing time: 12 Apr 2024, 16:55:13 UTC
Previous filing: 12 Oct 2023
Next filing: 01 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCSA	Common Stock	Options Exercise		+1,675	+6.1%		29,153	01 Jan 2024	Direct	F1, F2
transaction	PCSA	Common Stock	Tax liability	$1,504	-539	-1.8%	$2.79	28,614	01 Jan 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCSA	Restricted Stock Units	Options Exercise	$0	-1,675	-7.7%	$0.000000	20,132	01 Jan 2024	Common Stock	1,675	$0.000000	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Distribution of vested restricted shares.
F2	Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.